(Q42280296)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Recommendations for the management of hepatitis C virus infection among people who inject drugs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

16

Maria Prins

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

11

Heiner Wedemeyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

17

Gregory J Dore

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

Jason Grebely

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Geert Robaeys

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Stefan Mauss

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Joseph Moussalli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Andrea De Gottardi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Tracy Swan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Amber Arain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Achim Kautz

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Heino Stöver

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Martin Schaefer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Lynn Taylor

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Markus Backmund

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Olav Dalgard

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

International Network on Hepatitis in Substance Users

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

Clinical Infectious Diseases

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

57 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

S129-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23884061%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology of hepatitis C virus infection

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

What is killing people with hepatitis C virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treatment of hepatitis C infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Follow-up studies of treatment for hepatitis C virus infection among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treating hepatitis C in methadone maintenance patients: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treatment for hepatitis C virus infection among current injection drug users in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Should active injecting drug users receive treatment for chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

The management of chronic viral hepatitis: a Canadian consensus conference 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Limited uptake of hepatitis C treatment among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

The hepatitis C virus epidemic among injecting drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Mortality in heroin-assisted treatment in Switzerland 1994-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Ecstasy: a common cause of severe acute hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Environmental factors as disease accelerators during chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Influence of cannabis use on severity of hepatitis C disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Increased caffeine consumption is associated with reduced hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Non-invasive markers for hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Outreach screening of drug users for cirrhosis with transient elastography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Management of HCV and HIV infections among people who inject drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Pharmacokinetic interaction between telaprevir and methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Assessing the validity of self-reported medication adherence in hepatitis C treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Adherence to hepatitis C treatment in recovering heroin users maintained on methadone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Adherence to hepatitis C virus therapy and early virologic outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Alcohol use and treatment of hepatitis C virus: results of a national multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C virus reinfection following treatment among people who use drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Coinfection with HIV and hepatitis C virus in injection drug users and minority populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Current management of delta hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Previous Intravenous Substance Use and Outcome of Liver Transplantation in Patients With Chronic Hepatitis C Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Illicit drug use and liver transplantation: is there a problem and what is the solution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Liver transplantation for patients on methadone maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302

Association of caffeine intake and histological features of chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT302